Johnson And Johnson (JNJ) vs Pfizer (PFE)
JNJ and PFE are tied on the current QuantLink comparison, so the scorecard does not point to a single leader.
Side-by-side scorecard
As of Aug 21, 2026. Unavailable values are shown as — and excluded from the comparable-metric tally.
| Metric | Johnson & Johnson (JNJ) | Pfizer Inc. (PFE) |
|---|---|---|
| Size | ||
PriceContext only | — | — |
Market capContext only | $651.3B | $160.0B |
| Valuation | ||
P/E ratio | ✓31.29x | 36.84x |
PEG ratio | ✓-3.84x | -0.62x |
Price/book | 7.75x | ✓1.87x |
Price/sales | 6.72x | ✓2.51x |
EV/EBITDA | 20.12x | ✓16.78x |
| Profitability | ||
Gross margin | 70.5% | ✓71.3% |
Operating margin | ✓26.8% | 25.1% |
Net margin | ✓21.5% | 6.8% |
ROIC | — | 4.7% |
ROE | — | 5.1% |
EPS | — | — |
| Leverage | ||
Debt/equity | — | 0.74x |
| Dividend | ||
Dividend yield | — | — |
How the comparison is scored
QuantLink marks a row leader only when both companies have a numeric value and the metric has a fixed comparison direction. Lower values lead on valuation multiples and debt/equity, while higher values lead on profitability and dividend yield.
Price and market capitalization are shown for context only, so they do not receive a leader checkmark and do not affect the tally.